Luteolin is a naturally occurring flavonoid — a member of the polyphenol family of plant-derived compounds characterised by multiple phenolic groups that allow them to interact with proteins, enzymes, and cellular signalling pathways. It is classified as a plant secondary metabolite (PSM): a compound produced not for primary cell function, but for ecological advantages including defence against pathogens, UV protection, and stress adaptation (Kumar et al., 2022).

Its biological activity has made it a subject of study in traditional medicine for centuries. Modern research has now uncovered a more precise picture of how luteolin interacts with human metabolic pathways — and why its ability to modulate the enzyme fructokinase places it at the centre of an emerging area of metabolic science.

Unlike direct antioxidants that neutralise ROS after they are generated, luteolin's fructokinase inhibition prevents ROS production at source — a distinction explained in full in our hub on luteolin's role in reducing fructose-driven oxidative stress.

uteolin occurs naturally in a range of commonly consumed plant foods, though concentrations vary considerably and are generally modest in whole food form. A comprehensive breakdown ofwhich foods contain the highest concentrations of luteolin and how dietary intake compares to supplemental doses used in researchreveals an important practical gap between what food can deliver and what clinical studies have used.

Reference: Nabavi et al. (2015). Luteolin as an anti-inflammatory and neuroprotective agent.Brain Research Bulletin.

Despite its promising biological activity, luteolin faces a significant pharmacokinetic challenge: it is poorly absorbed in its natural form. While it contains hydroxyl groups (OH) capable of forming bonds with water, its dominant structural feature is a strong non-polar flavone skeleton — making the molecule fundamentally hydrophobic and resistant to absorption through the aqueous environment of the gastrointestinal tract (Nabavi et al., 2015).

This low natural bioavailability is a critical limitation. Even relatively high dietary intakes of luteolin-rich foods deliver only a fraction of the compound to target tissues. Standard supplement capsules using unformulated luteolin face the same barrier. For a detailed exploration of why luteolin's hydrophobic structure limits conventional absorption and how liposomal encapsulation fundamentally changes its delivery profile, the pharmaceutical rationale is well established.

How Liposomal Delivery Works?

Liposomal technology uses lipid vesicles — microscopic spheres composed of phospholipid bilayers — to encapsulate hydrophobic compounds like luteolin. The lipid exterior is compatible with cell membranes and the aqueous digestive environment simultaneously, allowing the encapsulated compound to travel through the gut without degradation and be delivered directly to target cells.

This approach increases both the proportion of luteolin absorbed and the consistency of that absorption — making it more likely that meaningful concentrations reach metabolically relevant tissues including the liver, where fructokinase is most active (Wu et al., 2018).

Of all luteolin's studied biological activities, its capacity to modulate fructokinase is the most metabolically significant for the modern disease burden. Fructokinase — formally ketohexokinase C (KHK-C) — is the enzyme that initiates fructose metabolism in the liver and intestine, converting fructose to fructose-1-phosphate in an unregulated, ATP-consuming reaction (Andres-Hernando et al., 2020). Unlike glucose metabolism, this process has no feedback control: it runs to completion regardless of cellular energy status, depleting ATP, generating uric acid, and triggering downstream metabolic dysfunction.

Preclinical studies suggest that luteolin's molecular structure allows it to bind to fructokinase's active site — the same site that normally accommodates fructose — competitively inhibiting or reducing the enzyme's activity. The result, observed in animal models, is increased urinary fructose excretion (fructose passing through without being metabolised) and reduced downstream uric acid production (Spiegel, 2023).

This mechanism positions luteolin differently from most metabolic supplements, which address downstream symptoms — inflammation, elevated blood sugar, or high triglycerides — after the damage has already occurred. By targeting fructokinase, luteolin intervenes upstream: at the moment fructose is metabolised, before the cascade of metabolic consequences begins.

For a deep dive into the research evidence on luteolin as a fructokinase inhibitor, its binding mechanism, the preclinical evidence, and what this means for individuals managing fructose-driven metabolic conditions, the science provides a compelling case for upstream intervention.

The downstream connection between fructokinase activity and uric acid overproduction is explored in detail in a dedicated piece on how luteolin's fructokinase modulation translates into measurable reductions in uric acid production and the metabolic relief that follows.

As you implement lifestyle changes, you'll want to track progress — explore biomarker tracking to measure your metabolic recovery progress in our testing hub.

Reference: Andres-Hernando et al. (2020). Deletion of fructokinase in the liver or intestine reveals differential effects. Cell Metabolism.

While fructokinase modulation is luteolin's most distinctive metabolic mechanism, it is far from its only studied benefit. As a potent antioxidant and anti-inflammatory compound, luteolin interacts with multiple cellular signalling pathways across organ systems — making it one of the most comprehensively studied flavonoids in preclinical and early clinical research.

For a structured comparison of luteolin versus quercetin — a closely related flavonoid — and which compound shows stronger evidence for fructose metabolism modulation versus other metabolic benefits, the mechanistic distinctions are important for understanding what makes luteolin uniquely relevant to fructokinase inhibition.

A detailed examination of luteolin's anti-inflammatory mechanisms and how its suppression of NF-kB and IL-6 pathways translates into clinically relevant outcomes in metabolic disease provides the biochemical foundation for many of the broader benefits above.

While much of luteolin's mechanistic evidence comes from preclinical (animal and cell) models, the Altilix study provides one of the most substantive human clinical datasets for its metabolic effects (Castellino et al., 2019). This six-month randomised, double-blind, placebo-controlled trial examined the effects of an artichoke-derived supplement standardised for chlorogenic acid and luteolin derivatives on patients with metabolic syndrome and non-alcoholic fatty liver disease (NAFLD).

Study design: Double-blind, placebo-controlled, 6 months. Participants: patients with metabolic syndrome. Formulation: Altilix — standardised artichoke extract containing luteolin derivatives and chlorogenic acid. All referenced benefits are from this specific study and should not be generalised to all luteolin formulations. Results are from a single study and require replication in larger trials before clinical recommendations can be made.

Key Findings

The study demonstrated significant improvements across several parameters that are central to NAFLD and metabolic syndrome:

• Triglyceride reduction: Meaningful decreases in circulating triglycerides — a direct marker of liver fat metabolism improvement and a core component of metabolic syndrome diagnosis
• Improved insulin sensitivity: Through combined antioxidant, anti-inflammatory, and lipid-modulating actions, supplementation was associated with improved glucose metabolism markers, including attenuation of NF-kB, TNF-alpha, and IL-6 — the primary inflammatory drivers of insulin resistance
• Liver cell protection: Antioxidant activity from artichoke-derived luteolin derivatives appeared to protect hepatocyte (liver cell) membranes, reduce fat-related oxidative damage, and improve bile-driven fat metabolism
• Ghrelin modulation: An unexpected finding was increased circulating ghrelin — suggesting a broader metabolic-hormonal effect that may counteract weight gain and support energy balance through appetite regulation pathways
• Independent of weight loss: Improvements in triglycerides and liver parameters occurred even where weight reduction was modest, suggesting a direct lipid metabolism effect rather than one secondary to caloric restriction

For a comprehensive breakdown of the Altilix study findings and what they suggest about luteolin's role in non-alcoholic fatty liver disease — the metabolic condition now affecting an estimated 1 in 4 adults globally, the clinical data represents the strongest available human evidence for luteolin as a metabolic intervention.

Reference: Castellino et al. (2019). Altilix supplement containing chlorogenic acid and luteolin improved hepatic and cardiometabolic parameters. Nutrients.

Metabolic syndrome — the clinical cluster of insulin resistance, abdominal obesity, elevated triglycerides, high blood pressure, and low HDL — is driven at the cellular level by three universal mechanisms: chronic inflammation, oxidative stress, and mitochondrial energy dysfunction. Luteolin addresses all three simultaneously through distinct but complementary pathways.

Its fructokinase inhibition reduces the primary enzymatic driver of uric acid overproduction and ATP depletion. Its NF-kB and IL-6 pathway suppression attenuates the chronic low-grade inflammation that degrades insulin receptor sensitivity. Its antioxidant activity reduces mitochondrial oxidative damage and helps preserve ATP production capacity. This multi-target profile makes luteolin one of the few natural compounds with mechanistic relevance to multiple components of metabolic syndrome simultaneously.

For a detailed examination of how luteolin addresses the root biochemical mechanisms of metabolic syndrome through its combined fructokinase, anti-inflammatory, and antioxidant actions, and how this compares to single-target pharmaceutical approaches, the evidence supports a complementary role in metabolic health strategies.

The broader context of how metabolic syndrome develops and why fructose metabolism is central to its progression is explored in depth in the LIV3 metabolic syndrome hub.

nsulin resistance is the single most consistent underlying feature connecting metabolic syndrome, NAFLD, type 2 diabetes, PCOS, and cardiovascular disease. Luteolin's anti-inflammatory and antioxidant mechanisms directly target several of the molecular pathways through which insulin resistance is both generated and maintained.

At the hepatic level — where fructokinase is most active and where fructose-driven fat accumulation (lipogenesis) is initiated — luteolin's dual action of reducing fructokinase activity and suppressing inflammatory signalling creates conditions for improved hepatocyte function and reduced ectopic fat deposition. For an in-depth look at the specific mechanisms through which luteolin may support insulin sensitivity — including its effects on IRS-1 signalling, hepatic lipid accumulation, and inflammatory cytokine suppression, the mechanistic picture supports its role as a complementary metabolic intervention.

The connection between dietary fructose, fructokinase-driven fat storage, and non-alcoholic fatty liver disease makes luteolin particularly relevant for the estimated 1 in 4 adults with hepatic steatosis — many of whom are unaware of the condition.

Reference: Jung et al. (2022). Dietary Fructose and Fructose-Induced Pathologies. Annual Review of Nutrition.

Cardiovascular disease risk in metabolic syndrome is driven substantially by the same mechanisms luteolin addresses at the cellular level: oxidative stress degrading endothelial function, chronic inflammation driving arterial stiffness, uric acid activating the renin-angiotensin system, and elevated triglycerides accelerating atherosclerosis.

Preclinical evidence suggests luteolin may support cardiovascular health through multiple pathways: reducing LDL oxidation (a key early step in atherosclerotic plaque formation), improving nitric oxide bioavailability (supporting healthy blood vessel dilation), attenuating vascular smooth muscle inflammation, and reducing the uric acid-mediated vascular damage documented in hyperuricemia research.

A detailed review of the preclinical and observational evidence for luteolin's cardiovascular protective mechanisms — including its effects on endothelial function, LDL oxidation, and inflammatory vascular remodelling provides the cardiovascular context for its role in metabolic health. For individuals specifically concerned with blood pressure, a focused look at luteolin's proposed mechanisms for supporting healthy blood pressure through nitric oxide and renin-angiotensin pathway modulation offers relevant mechanistic detail.

One of luteolin's most extensively studied areas outside metabolic disease is its neuroprotective activity. As a small, lipophilic molecule, luteolin is able to cross the blood-brain barrier — a critical prerequisite for any compound intended to have direct neurological effects. Once in the central nervous system, its antioxidant and anti-inflammatory mechanisms interact with neurons and glial cells in ways that may support long-term brain health.

Brain fog — the cognitive symptom most directly connected to fructokinase-driven ATP depletion in neurons — may be one of the more immediate expressions of luteolin's metabolic brain protection. Research exploring how luteolin's fructokinase modulation and mitochondrial support may address the metabolic origins of brain fog and cognitive sluggishness connects the mechanistic dots between fructose metabolism and neurological energy status.

For broader neuroprotective applications, a review of the preclinical evidence for luteolin's neuroprotective mechanisms — including its antioxidant, anti-inflammatory, and mitochondrial effects in neural tissue provides the scientific foundation for its ongoing investigation in neurological research.

Preclinical research has examined luteolin's potential relevance to Alzheimer's disease — a condition characterised by neuroinflammation, amyloid plaque formation, and progressive neuronal oxidative damage. Research exploring what the preclinical evidence suggests about luteolin's mechanisms in Alzheimer's disease research — including its effects on neuroinflammation, amyloid processing, and neuronal oxidative stress represents a growing area of investigation. Similarly, research into luteolin's potential neuroprotective role in Parkinson's disease models, and the specific mechanisms through which it may attenuate dopaminergic neuron loss is at an early but promising stage.

*All research referenced in this section is preclinical or based on early observational data. None of the following should be interpreted as evidence that luteolin treats, prevents, or cures any neurological condition. These are areas of active scientific investigation, not established clinical applications.*

Autism Spectrum Research

Luteolin has attracted research interest in the context of autism spectrum conditions, primarily through its mast cell stabilisation and neuroinflammation-reducing mechanisms. Research highlighting new findings on luteolin's potential to protect against autism-related metabolic and neuroinflammatory damage in preclinical models — including its effects on mast cell activation and the neuroinflammatory environment — is among the more actively developing areas of luteolin neuroscience.

Multiple Sclerosis, Schizophrenia & Huntington's Research

Luteolin's anti-neuroinflammatory profile has led to its investigation in several other neurological conditions where chronic central nervous system inflammation plays a pathological role. Preclinical data on luteolin and multiple sclerosis models, and the specific inflammatory pathways it appears to modulate in demyelinating disease research adds to a picture of broad neuroprotective relevance. Early investigations into its relevance to schizophrenia-related neuroinflammation and oxidative stress pathways, and separately to Huntington's disease models where luteolin's mitochondrial protective effects have been examined, extend this research context further — though all remain at early investigational stages.

For women considering luteolin supplementation — particularly those managing PCOS or navigating the hormonal changes of perimenopause — a key question is how luteolin interacts with female sex hormones. A thorough research review of whether luteolin affects oestrogen and progesterone levels, its classification relative to phyto-oestrogens, and the evidence for its hormonal effects in women's health research provides an important distinction: luteolin is not classified as a classical phyto-oestrogen. Its primary metabolic mechanisms operate upstream at the fructokinase and inflammatory signalling level, rather than through direct oestrogen receptor activity.

This distinction matters for women with PCOS who may be cautious about compounds that modulate oestrogen receptor signalling. Luteolin's mechanism for supporting PCOS symptoms — via insulin sensitivity improvement, uric acid reduction, and anti-inflammatory action — does not follow the phyto-oestrogenic pathway. Research exploring the evidence for luteolin's role in PCOS management — including its effects on insulin resistance, androgen-driven symptoms, and metabolic health in women with hormonal dysregulation builds on the metabolic model of PCOS explored in detail in the LIV3 PCOS hub.

The connection between PCOS, fructose metabolism, and insulin resistance is explored in full in the LIV3 PCOS hub — covering the complete fructose-to-hormonal-symptom cascade and how addressing upstream metabolic drivers may support downstream hormonal balance.

As GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) have entered mainstream awareness, questions about natural alternatives and complementary approaches to weight management have increased significantly. A direct, evidence-based comparison of luteolin and semaglutide — their mechanisms, the strength of evidence for each, their appropriate use cases, and the key differences in how they address metabolic dysfunction and weight addresses one of the most common questions in the metabolic supplement space.

The honest answer is that luteolin and GLP-1 agonists operate through fundamentally different mechanisms and should not be directly compared as alternatives. Semaglutide directly activates GLP-1 receptors to suppress appetite and slow gastric emptying. Luteolin modulates fructokinase to reduce upstream metabolic disruption. For individuals seeking to address the metabolic root causes of weight gain — including fructose-driven insulin resistance, uric acid accumulation, and mitochondrial dysfunction — rather than appetite suppression, luteolin represents a meaningfully different approach.

For individuals interested specifically in what the evidence says about luteolin's effects on body weight and fat metabolism — and how its fructokinase and anti-inflammatory mechanisms create conditions that may support healthy weight management, the mechanistic case is distinct from and complementary to appetite-based approaches.

For physically active people and athletes, the fructokinase question takes on a specific relevance: sports nutrition products, energy drinks, and recovery formulations are frequently among the highest sources of concentrated fructose — often in the form of high-fructose corn syrup, sucrose, or concentrated fruit sugars. The acute ATP depletion triggered by fructokinase activity is particularly counterproductive in a context where ATP availability directly determines muscular performance and recovery.

Research examining whether luteolin's fructokinase modulation represents a sensible metabolic strategy for healthy individuals and athletes managing fructose exposure in their nutrition addresses the performance-specific context directly. Beyond fructokinase, luteolin's antioxidant and mitochondrial support properties have independent relevance to athletic performance — where oxidative stress from intense exercise and mitochondrial efficiency both affect recovery and output. The connection between luteolin's cellular energy support mechanisms and the ATP preservation that follows reduced fructokinase activity makes the compound particularly relevant for anyone whose metabolic environment involves regular fructose exposure alongside high energy demands.

One of the most important — and most underappreciated — aspects of modern fructose exposure is that it does not require sugar consumption. The polyol pathway converts glucose to sorbitol, then sorbitol to fructose internally, entirely independent of dietary intake (Lanaspa et al., 2014). This endogenous fructose production is triggered by physiological conditions that are endemic to modern life: chronic psychological stress elevating cortisol and blood glucose; dehydration and high sodium intake activating osmotic stress responses; hyperglycaemia from refined carbohydrate consumption even without added fructose.

The practical implication is significant: eliminating added sugar from the diet reduces fructose exposure but does not eliminate it. For individuals whose elevated uric acid, insulin resistance, or metabolic symptoms persist despite dietary restriction, endogenous fructose production via the polyol pathway is often the missing explanation. Luteolin's fructokinase modulation addresses metabolically generated fructose with the same mechanism it addresses dietary fructose — because from the enzyme's perspective, the source is irrelevant.

This makes luteolin supplementation a daily metabolic strategy rather than simply a complement to sugar restriction. For a full exploration of how fructokinase activity drives metabolic dysfunction whether fructose comes from food or your own cells — and why targeting the enzyme rather than the dietary source may be the more effective strategy, the science supports a fundamentally different framing of fructose management.

Reference: Lanaspa et al. (2014). Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. JASN.

*Research referenced in this section is primarily preclinical. These findings are not evidence that luteolin treats any medical condition and should not be used to make clinical decisions.*

Beyond its primary metabolic and neurological research areas, luteolin has been examined across a broader range of biological contexts. Research into luteolin's effects on gut microbiome composition and intestinal barrier function — including its anti-inflammatory activity in the gut epithelium connects its broader polyphenol properties to digestive health. For individuals managing blood glucose, a review of the preclinical and clinical evidence for luteolin's effects on blood sugar regulation and insulin signalling in the context of type 2 diabetes extends the insulin sensitivity research to diabetic management contexts.

Research on luteolin's potential anxiolytic and mood-supporting properties — including its effects on neuroinflammatory pathways linked to anxiety and depressive symptomatology in preclinical models represents an emerging area of interest given the documented connection between metabolic dysfunction and mood disorders. In the area of oncology research, preclinical studies examining luteolin's effects on tumour cell growth, apoptosis induction, and angiogenesis suppression have generated scientific interest — though this research is at an early stage and should not be interpreted as evidence of cancer prevention or treatment efficacy.

Luteolin has a generally favourable safety profile in both dietary and supplemental contexts based on available evidence. It is a naturally occurring compound consumed in food across all human populations. Clinical and preclinical toxicology studies have not identified serious adverse effects at typical supplemental doses. However, as with any bioactive compound, individual variation, potential herb-drug interactions, and the specific considerations of certain populations warrant attention.

A comprehensive guide to luteolin's safety profile, reported side effects, drug interactions, and the populations who should exercise caution or consult a healthcare provider before supplementing provides the full safety picture. A separate, practical reference on luteolin dosage — including the ranges used in clinical research, how liposomal formulations affect dosing considerations, and how to approach supplementation addresses the most common practical question for new users.

*Pregnant and breastfeeding women should not supplement with luteolin without medical supervision. Individuals taking anticoagulant, antiplatelet, or immunosuppressant medications should consult a healthcare provider before use. Do not use luteolin supplementation as a substitute for prescribed medical treatment.*

SugarShield was developed with a specific metabolic target: fructokinase — the enzyme that initiates fructose's unregulated, ATP-depleting, uric acid-generating pathway. By delivering luteolin in liposomal form alongside tart cherry extract, the formulation is designed to address fructose metabolism from both the production and the inflammatory downstream angles simultaneously.

Liposomal delivery solves luteolin's primary limitation — its natural hydrophobicity and poor bioavailability — by encapsulating it in lipid vesicles that protect it from early metabolism and deliver it to target tissues including the liver, where fructokinase activity is highest. Tart cherry provides anthocyanin support for uric acid clearance and anti-inflammatory activity at the downstream end of the same pathway.

It is not just about taking a supplement. It is about supporting your body at the precise point where metabolic imbalance begins — the moment fructose is metabolised, whether that fructose came from your food or from your own cells.*

• The Complete Fructose Metabolism Guide — foundational science
• Fructokinase Hub — the enzyme luteolin targets
• Luteolin as a Fructokinase Inhibitor: The Evidence
• Why Liposomal Delivery Changes Luteolin's Effectiveness
• Luteolin vs Semaglutide: An Honest Comparison
• Luteolin and Metabolic Syndrome: A Natural Warrior
• Luteolin and Brain Fog: The Metabolic Connection
• Luteolin and Alzheimer's: Preclinical Research Overview
• Luteolin and Female Hormones: Oestrogen and Progesterone Research
• Luteolin and PCOS: The Insulin Resistance Connection
• Luteolin for Athletes: Fructokinase Inhibition and Performance
• Luteolin, Fructokinase and Uric Acid: The Production Chain
• Luteolin and Insulin Resistance: Cellular Mechanisms
• Luteolin and NAFLD: The Altilix Study and Beyond
• Luteolin and Cellular Energy: ATP Preservation Research
• Luteolin Safety: Side Effects, Interactions and Precautions
• Luteolin Dosage Guide: What Research Doses Tell Us
• Luteolin Food Sources: Dietary Intake vs Supplemental Doses
• Luteolin vs Quercetin: Which Flavonoid for Metabolic Health?

• Andres-Hernando, A., Orlicky, D. J., Kuwabara, M., Ishimoto, T., Nakagawa, T., Johnson, R. J., & Lanaspa, M. A. (2020). Deletion of Fructokinase in the Liver or in the Intestine Reveals Differential Effects on Sugar-Induced Metabolic Dysfunction. Cell metabolism, 31(1), 117-127. https://doi.org/10.1016/j.cmet.2020.05.0
• Castellino, G., Nikolic, D., Magán-Fernández, A., Malfa, G. A., Chianetta, R., Patti, A. M., Amato, A., Montalto, G., Toth, P. P., Banach, M., Cicero, A. F. G., Rizzo, M. (2019). Altilix®Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. Nutrients, 11(11), 2580. https://doi.org/10.3390/nu11112580
• Guixia Wu Jing Li Jinqiao Yue Shuying Zhang Kurexi Yunusi. (2018). Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma. Molecular medicine reports, 17(2), 2456-2464. https://doi.org/10.3892/mmr.2017.8185
• Jonathan Spiegel. (2023). The potential therapeutic roles of quercetin and luteolin in hereditary fructose intolerance. Medical Hypotheses, 178(111139). https://doi.org/10.1016/j.mehy.2023.111139
• Lanaspa, M. A., Ishimoto, T., Cicerchi, C., Tamura, Y., Roncal-Jimenez, C. A., Chen, W., Tanabe, K., Andres-Hernando, A., Orlicky, D. J., Finol, E., Inaba, S., Li, N., Rivard, C. J.,, & Kosugi, T., Sanchez-Lozada, L. G., Petrash, J. M., Sautin, Y. Y., Ejaz, & A. A., Kitagawa, W., Garcia, G. E., … Johnson, R. J. (2014). Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. Journal of the American Society of Nephrology : JASN, 25(11), 2526–2538. https://doi.org/10.1681/ASN.2013080901
• Li, M., Gu, X., Yang, J., Zhang, C., Zhou, Y., Huang, P., Wang, X., Zhang, L., Jiang, L., Zhai, L., Yu, M., Cheng, G., & Yang, L. (2025). Luteolin: A potential therapeutic agent for respiratory diseases. European journal of pharmacology, 999(177699). https://doi.org/10.1016/j.ejphar.2025.177699
• Satish Kumar, Rajni Saini, Priyanka Suthar, Vikas Kumar. (2022). Plant Secondary Metabolites: Their Food and Therapeutic Importance. Plant Secondary Metabolites, 371-413. http://dx.doi.org/10.1007/978-981-16-4779-6_12
• Seyed Fazel Nabavi, Nady Braidy, Olga Gortzi, Eduardo Sobarzo-Sanchez, Maria Daglia, KrystynaSkalicka-Woźniak, Seyed Mohammad Nabavi. (2015). Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Research Bulletin, 112(A), 1-11. https://doi.org/10.1016/j.brainresbull.2015.09.002
• Sunhee Jung, Hosung Bae, Won-Suk Song, Cholsoon Jang. (2022). Dietary Fructose and Fructose-Induced Pathologies. ANNUAL REVIEW OF NUTRITION, 42(2022), 45-66. https://doi.org/10.1146/annurev-nutr-062220-025831